About us
Services & Solutions
Chemistry DMPK Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry Parallel Synthesis
Flow Chemistry Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Pre-Formulation Formulation, Analytical and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
CN EN
×
news
Company News Events Insights Webinars Virtual Tours
Leadingtac Presents 2023 Best Partner Award to BioDuro-Sundia Chemistry Team
Shanghai, November 10, 2023 – Leadingtac (Leading Tac Pharmaceutical Co., Ltd) representatives Dr. Yan Feng, CEO and Dr. Zhengqing Ye, Senior Director of Chemistry, presented the onsite BioDuro-Sundia
November 10, 2023
Lynk Pharmaceuticals Presents Long-Term Outstanding Service Award to BioDuro-Sundia Chemistry Team
Shanghai, September 25, 2023 – Lynk Pharmaceuticals representatives Dr. Michael Vazquez, Executive Vice President and Head of Chemistry, Dr. Li Xiaodong, Senior Director of Chemistry, and Dr. Su Lin,
September 25, 2023
Congratulate Zhiben Pharma for Receiving China CDE Implied License to Initiate Clinical Trials for Antimicrobial Drug ZB-001
Shanghai, August 1, 2023 – ZB-001, a new antimicrobial drug developed by BioDuro-Sundia partners Zhiben Pharma, has received the implied license from the China CDE to initiate clinical trials. ZB-001
August 01, 2023
BioDuro-Sundia Jiangsu Site Re-establishes Legacy Operations in Radiometric Assays
​Wuxi, July 6, 2023 – Supporting clients in the high-growth in vitro drug discovery industry, BioDuro-Sundia Discovery Biology Department is proud to announce our enhanced formats and selection of biochemica
July 06, 2023
Salubris Pharmaceuticals SAL0119 IND Application for Treatment of Ankylosing Spondylitis and Rheumatoid Arthritis Accepted by FDA
Shanghai, June 30, 2023 – Salubris Pharmaceuticals, a partner of BioDuro-Sundia, announced that an investigational new drug (IND) application for SAL0119 has been accepted by the FDA.
June 30, 2023
Total 84 12345678...1617
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all